A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.

What similarly acting projects are still unpartnered?

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

The small cap biotech Instil Bio tries to follow in Summit’s slipstream.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.

The company defends its cancer strategy, and says it's not a me-too developer.

Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.